Turmeric Combined with Thalidomide Effectively Kills Cancer Cells|
Wednesday, August 21, 2013
Researchers combined structural features from anti-nausea drug thalidomide with common kitchen spice turmeric to create hybrid molecules that effectively kill multiple myeloma cells.
Chemists Devise New Way to Prepare Molecules for Drug Testing
Monday, August 19, 2013
Metal-catalyzed cross-couplings of carbon bonds could enable creation of libraries of drug candidates to accelerate drug discovery.
Breaking up the Superbugs’ Party
Friday, August 16, 2013
The fight against antibiotic-resistant superbugs has taken a step forward thanks to a new discovery by scientists.
Hepregen Corporation and The Hamner Institutes for Health Sciences Announce Research Partnership
Tuesday, August 13, 2013
Agreement provides opportunity to collaborate on research supporting next generation in vitro micro-liver analysis associated with pharmaceutical and chemical product development.
Harlan Contract Research Services Cytotest Cell Research Selected for Membership in EU-NETVAL
Monday, August 12, 2013
Harlan Contract Research Services (CRS) has been named one of the first laboratories selected for inclusion in the European Union Network of Laboratories for the Validation of Alternative Methods.
Hepregen Announces Appointment of Dr. Michael Holsapple
Wednesday, August 07, 2013
Appointment adds respected leader in toxicology to Hepregen’s senior management team, reflecting ongoing commitment of Hepregen’s strategic investor, Battelle Memorial Institute.
£4.8m Funding Awarded for Smart Approaches to Reduce Animal use in Science
Wednesday, July 31, 2013
NC3Rs grants will develop new testing methods, infrastructure and technologies.
BD Announces Approval of Safety Integrated IV Catheter System for Subcutaneous Therapy in Europe
Tuesday, July 23, 2013
BD Saf-T-Intima™ increases patient comfort and in-dwell times while enabling cost savings and reducing the risk of sharps injuries and infection.
Discovered a Future Therapeutic Target for Lung Cancer Treatment
Monday, July 22, 2013
One of the goals of research in cancer genetics and molecular biology is to get an "on demand" treatment, with maximum effect and minimal toxicity.